Analyzing Mallinckrodt PLC (MNK) and Rockwell Medical (RMTI)
Mallinckrodt PLC (NYSE: MNK) and Rockwell Medical (NASDAQ:RMTI) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.
Volatility & Risk
Mallinckrodt PLC has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500.
This is a breakdown of current ratings and target prices for Mallinckrodt PLC and Rockwell Medical, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Mallinckrodt PLC presently has a consensus price target of $70.54, suggesting a potential upside of 71.33%. Rockwell Medical has a consensus price target of $9.33, suggesting a potential upside of 45.83%. Given Mallinckrodt PLC’s stronger consensus rating and higher possible upside, analysts plainly believe Mallinckrodt PLC is more favorable than Rockwell Medical.
Insider & Institutional Ownership
97.5% of Mallinckrodt PLC shares are owned by institutional investors. Comparatively, 21.4% of Rockwell Medical shares are owned by institutional investors. 0.8% of Mallinckrodt PLC shares are owned by company insiders. Comparatively, 15.9% of Rockwell Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Mallinckrodt PLC and Rockwell Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Mallinckrodt PLC and Rockwell Medical’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Mallinckrodt PLC||$3.27 billion||1.22||$666.60 million||$4.10||10.04|
|Rockwell Medical||$54.04 million||6.13||-$21.07 million||($0.42)||-15.24|
Mallinckrodt PLC has higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Mallinckrodt PLC, indicating that it is currently the more affordable of the two stocks.
Mallinckrodt PLC beats Rockwell Medical on 10 of the 14 factors compared between the two stocks.
About Mallinckrodt PLC
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.
About Rockwell Medical
Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company’s drug products include Triferic (ferric pyrophosphate citrate) and Calcitriol (Active Vitamin D) Injection. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Calcitriol (active vitamin D) injection is indicated for treatment of secondary hyperparathyroidism in dialysis patients.
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.